265. Strategy Trials: A New Paradigm in Infectious Diseases Research
Saturday, October 6, 2018: 2:00 PM-3:15 PM
Room: W 2005-2024

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • explain the rationale for performing strategy trials in infectious diseases
  • summarize data for two of the more common infections addressed by strategy

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Pharmacists, Public health practitioners, Researchers, Scientists

Tracks: Investigative ID, Pediatric ID, Trainee, Epidemiology and Infection Control, Adult ID

Moderators:  Samuel Shelburne, MD, PhD, FIDSA, MD Anderson Cancer Center and Vance G. Fowler Jr., MD, Duke University Medical Center

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-275-L04-P


S. Shelburne, None

V. G. Fowler Jr., Cerexa/Actavis/Allergan, Pfizer, Advanced Liquid Logics, NIH, MedImmune, Basilea Pharmaceutica, Karius, ContraFect, Regeneron Pharmaceuticals, and Genentech: Grant Investigator , Grant recipient . Achaogen, Astellas Pharma, Arsanis, Affinergy, AmpliPhi, Basilea Pharmaceutica, Bayer, Cerexa Inc., ContraFect, Cubist, Debiopharm, Durata Therapeutics, Grifols, Genentech, MedImmune, Merck, The Medicines Company, Pfizer, Novartis, NovaDigm Therapeutics: Consultant , Consulting fee . Theravance Biopharma, Inc., and Green Cross: Lecturer , Speaker honorarium . UpToDate: Author , Royalties .

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.